NCT03634826 (MEDAL) is a clinical trial in Carcinoma, sponsored by Peking University People's Hospital.

Who is sponsoring NCT03634826?

NCT03634826 is sponsored by Peking University People's Hospital.

What condition does NCT03634826 study?

NCT03634826 studies Carcinoma, Lung Cancer, NSCLC, Lung Neoplasm.

Is NCT03634826 still recruiting?

NCT03634826 is currently status unknown. Last updated 26 June 2020.

Last reviewed 2020-06-26 · How we verify

NCT03634826: MEDAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).

Status unknown Last updated 26 June 2020

What this trial tests

trial in Carcinoma in 200 participants. Status unknown.

Timeline

15 August 2018

Primary endpoint
31 December 2021

1 January 2022

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	15 August 2018
Primary completion	31 December 2021
Estimated completion	1 January 2022
Sites	1 location across China

Conditions studied

Carcinoma — all drugs for Carcinoma →
Lung Cancer — all drugs for Lung Cancer →
NSCLC — all drugs for NSCLC →
Lung Neoplasm — all drugs for Lung Neoplasm →

Sponsor

Peking University People's Hospital

Who can join

Adults 18 to 80, any sex, with Carcinoma or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Conduct a prospective study to confirm the value of circulating tumor DNA and its aberrant methylation in longitudinal monitoring of surgical lung cancer patients.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.
Li L, Sun Y. · · 2024 · cited 52× · PMID 39525954 · DOI 10.1002/mco2.766
Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact.
Honoré N, Galot R, van Marcke C, Limaye N, et al · · 2021 · cited 50× · PMID 34771526 · DOI 10.3390/cancers13215364
Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study.
Kang G, Chen K, Yang F, Chuai S, et al · · 2019 · cited 21× · PMID 31195991 · DOI 10.1186/s12885-019-5751-9
Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer.
Chen K, Kang G, Zhang Z, Lizaso A, et al · · 2023 · cited 20× · PMID 37452374 · DOI 10.1186/s12916-023-02954-z
Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer.
Peng Y, Li Z, Fu Y, Pan Y, et al · · 2023 · cited 11× · PMID 36761954 · DOI 10.3389/fonc.2023.1011810
Use of on-therapy ctDNA monitoring in a patient with <i>KIF5B-RET</i> fusion positive advanced non-small cell lung cancer: a case report.
Yeung V, Kim C, Kiedrowski LA, Liu SV, et al · · 2022 · cited 3× · PMID 35242632 · DOI 10.21037/tlcr-21-571
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review.
Wang Y, Shao W, Li H, Zhao P, et al · · 2025 · cited 2× · PMID 40248720 · DOI 10.21037/tlcr-24-942

Verify or expand the search:

Other recruiting trials for Carcinoma

Currently open trials in the same condition.

NCT07257094 — Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Reha · recruiting
NCT06969534 — Safety and Efficacy of Pucotenlimab in pLECC · Phase 2 · recruiting
NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting
NCT07470827 — Evaluation of 'WAYMED Endo CL CS' for Automated Detection and Diagnosis of Colorectal Adenoma and Non-Adenoma Lesions · active not recruiting
NCT06317311 — A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recu · Phase 2 · active not recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03634826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 26 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03634826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing